We are live on
!
Find out more
ProShare Advisors Portfolio holdings
AUM
$67.5B
1-Year Est. Return
28.09%
This Quarter
Est. Return
+11.21%
1 Year Est. Return
+28.09%
3 Year Est. Return
+88.43%
5 Year Est. Return
+118.21%
10 Year Est. Return
+464.8%
AUM
$32.7B
AUM Growth
+$4.24B
(+15%)
Cap. Flow
+$1.96B
Cap. Flow
% of AUM
5.98%
Top 10 Holdings %
Top 10 Hldgs %
24.15%
Holding
1,955
New
105
Increased
595
Reduced
1,083
Closed
168
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Target
TGT
|
+$183M |
| 2 |
J.M. Smucker
SJM
|
+$174M |
| 3 |
C.H. Robinson
CHRW
|
+$169M |
| 4 |
Microsoft
MSFT
|
+$165M |
| 5 |
Nordson
NDSN
|
+$161M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
VF Corp
VFC
|
+$153M |
| 2 |
Caterpillar
CAT
|
+$44.2M |
| 3 |
Franklin Resources
BEN
|
+$41.9M |
| 4 |
Air Products & Chemicals
APD
|
+$35.1M |
| 5 |
Pentair
PNR
|
+$32.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 25.57% |
| 2 | Industrials | 11.94% |
| 3 | Consumer Staples | 11.7% |
| 4 | Consumer Discretionary | 10.33% |
| 5 | Healthcare | 10.29% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
NKLA
1676
DELISTED
Nikola Corporation Common Stock
NKLA
| $48.3K | ﹤0.01% |
1,330
-164
| -11% | -$10.8K |
|
1677
Sutro Biopharma
STRO
$379M
| $47.7K | ﹤0.01% |
1,033
-136
| -12% | -$8.63K |
|
|
CTEV
1678
Claritev Corp
CTEV
$368M
| $47.1K | ﹤0.01% |
1,112
-104
| -9% | -$4.7K |
|
1679
Solid Power
SLDP
$468M
| $47K | ﹤0.01% |
15,606
-1,454
| -9% | -$4.39K |
|
|
SLGC
1680
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
| $46.2K | ﹤0.01% |
18,128
-1,129
| -6% | -$3.23K |
|
1681
Tango Therapeutics
TNGX
$4.34B
| $45.8K | ﹤0.01% |
11,602
-1,691
| -13% | -$9.81K |
|
1682
MiMedx Group
MDXG
$626M
| $45.3K | ﹤0.01% |
13,281
-1,238
| -9% | -$4.79K |
|
1683
Humacyte
HUMA
$168M
| $43.5K | ﹤0.01% |
14,068
-2,025
| -13% | -$5.76K |
|
|
NGM
1684
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $42.6K | ﹤0.01% |
10,447
-1,514
| -13% | -$7K |
|
|
HLTH
1685
DELISTED
Cue Health Inc. Common Stock
HLTH
| $42.2K | ﹤0.01% |
23,174
-3,195
| -12% | -$6.94K |
|
1686
Xeris Biopharma Holdings
XERS
$1.44B
| $40.8K | ﹤0.01% |
+25,011
| New | +$31.3K |
|
|
PTRA
1687
DELISTED
Proterra Inc. Common Stock
PTRA
| $40K | ﹤0.01% |
26,317
-2,454
| -9% | -$9.23K |
|
|
KLRS
1688
Kalaris Therapeutics
KLRS
$88.7M
| $39.9K | ﹤0.01% |
441
-68
| -13% | -$8.66K |
|
|
AMRN
1689
Amarin Corp
AMRN
$284M
| $39.7K | ﹤0.01% |
1,324
-336
| -20% | -$11.8K |
|
1690
Nautilus Biotechnolgy
NAUT
$215M
| $39.5K | ﹤0.01% |
14,268
-2,181
| -13% | -$4.58K |
|
1691
Senseonics Holdings Inc
SENS
$254M
| $39.5K | ﹤0.01% |
2,783
-260
| -9% | -$5.22K |
|
|
TDAY
1692
USA Today Co
TDAY
$1.23B
| $39.1K | ﹤0.01% |
20,936
-1,853
| -8% | -$4.34K |
|
1693
Bionano Genomics
BNGO
$12.7M
| $39.1K | ﹤0.01% |
59
-5
| -8% | -$4.44K |
|
|
NPKI
1694
NPK International
NPKI
$1.21B
| $39.1K | ﹤0.01% |
10,153
-946
| -9% | -$4.14K |
|
1695
TETRA Technologies
TTI
$1.23B
| $38.8K | ﹤0.01% |
14,652
-1,366
| -9% | -$4.75K |
|
|
NVTA
1696
DELISTED
Invitae Corporation
NVTA
| $38.7K | ﹤0.01% |
28,701
-2,828
| -9% | -$5.57K |
|
1697
Clover Health Investments
CLOV
$2.28B
| $38.4K | ﹤0.01% |
45,468
-4,240
| -9% | -$4.64K |
|
1698
Inovio Pharmaceuticals
INO
$79.8M
| $38K | ﹤0.01% |
3,866
-504
| -12% | -$8.59K |
|
1699
Ouster
OUST
$2.29B
| $37.9K | ﹤0.01% |
4,530
+2,663
| +143% | +$30.9K |
|
|
DHC
1700
Diversified Healthcare Trust
DHC
$2.26B
| $37.8K | ﹤0.01% |
27,997
-2,612
| -9% | -$2.7K |
|
Similar funds
ProShare Advisors's Q1 2023 Portfolio in Review
As of Q1 2023, ProShare Advisors held 1,955 positions worth $32.7B, up 15% from $28.5B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
ProShare Advisors deployed $1.96B of net new capital in Q1 2023, opening 105 new positions and adding to 595 existing holdings. Its largest new stake was Target: 1,112,637 shares worth $184M.
By sector, the portfolio is most concentrated in Technology at 26% of assets, up from 22% a quarter earlier, followed by Industrials and Consumer Staples.
On the sell side, the largest reduction was VF Corp, an estimated $153M trimmed.
- ProShare Advisors's largest Q1 2023 buy was Target: 1,112,637 shares worth $184M.
- ProShare Advisors added most to J.M. Smucker in Q1 2023, an estimated $174M increase.
- ProShare Advisors's biggest Q1 2023 reduction was VF Corp, cutting an estimated $153M.
- ProShare Advisors fully exited South Jersey Industries, Inc. in Q1 2023, selling an estimated $10.2M.
- ProShare Advisors's ten largest holdings make up 24% of its $32.7B portfolio in Q1 2023.
- ProShare Advisors opened 105 new positions and closed 168 in Q1 2023.
- ProShare Advisors's portfolio value rose 15% quarter-over-quarter to $32.7B.
Based on ProShare Advisors's 13F filing for Q1 2023, filed 12 May 2023.